Research Paper Volume 13, Issue 20 pp 23810—23830

CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer

(A, C–J) CCR5 is positively correlated with good prognostic markers of anti-immune checkpoint therapies such as IFNG, IL12B, CD40, ABCB11, NFκB2, RELB, MAP3K14, CD28 and LAG3. (B) The correlation between the expression of CCR5 and IL12A does not have statistical significance (p = 0.0624).

Figure 8. (A, CJ) CCR5 is positively correlated with good prognostic markers of anti-immune checkpoint therapies such as IFNG, IL12B, CD40, ABCB11, NFκB2, RELB, MAP3K14, CD28 and LAG3. (B) The correlation between the expression of CCR5 and IL12A does not have statistical significance (p = 0.0624).